Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00260832
Status:
COMPLETED
Last Update Posted:
2019-09-11
First Post:
2005-12-01
Brief Title:
Trial of Decitabine in Patients With Acute Myeloid Leukemia
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
Randomized Phase 3 Trial of Decitabine Versus Patients Choice With Physicians Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
COMPLETED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the results in older patients who have newly diagnosed or secondary acute myeloid leukemia AML and who are to either receive decitabine or patients choice with the physicians advice of either cytarabine or supportive care medication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None